

Today's Information

Provided by: Senhwa Biosciences, Inc.

SEQ_NO 1 Date of announcement 2026/03/18 Time of announcement 06:12:23

Subject Senhwa's CX-5461 photodynamic therapy study shows significantly improved anti-tumor activity and survival; selected for poster presentation at AACR 2026.

Date of events 2026/03/18 To which item it meets paragraph 53

Statement

1.Date of occurrence of the event:2026/03/18
 2.Company name:Senhwa Biosciences Inc.
 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office
 4.Reciprocal shareholding ratios:Not applicable
 5.Cause of occurrence:
 (1) The Company's investigational drug Pidnarulex (CX-5461) is known to possess photosensitivity and the ability to induce photoactivation responses. The results of this novel application study confirm that CX-5461 can function as a highly efficient photosensitizer. Upon ultraviolet (UV) irradiation, it generates reactive oxygen species (ROS), leading to a significant increase in oxidative DNA damage. At the originally applied concentration, its cytotoxicity against cancer cells increased by approximately tenfold under light activation. These findings reveal a photo-reactive mechanism of action for CX-5461, in which G-quadruplex (G4) binding and light-induced ROS generation act synergistically to substantially enhance anti-tumor activity and significantly prolong survival. This breakthrough approach may support the development of a cross-indication (non-indication-restricted) therapeutic strategy applicable to superficial tumors, skin cancers, and localized treatment settings. The abstract of these findings has been selected for poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR).
 The Company's Chief Medical Officer, Dr. Pin-Yen Huang, and Associate Director of Clinical Research, Dr. Kai-Wei Hsueh, will attend and present the results of this novel photodynamic therapy approach.
 Presentation Details:
 Session Category: Clinical Research
 Session Title: Radiation and Photodynamic Therapy Response Modifiers
 Session Time: April 21, 2026, 2:00-5:00 PM
 Location: Poster Section 46
 Poster Board Number: 26
 Poster Number: 6625
 The full abstract was made available online on March 17, 2026 at 4:30 PM (ET) via the AACR official website (<https://www.aacr.org/>).
 For Senhwa, this discovery represents another breakthrough therapeutic application of Pidnarulex (CX-5461). The AACR Annual Meeting is widely recognized as a premier global platform for validating innovative science, presenting first-in-class mechanisms, and enhancing international visibility. Research presented at AACR frequently shapes future biomedical R&D directions and facilitates licensing partnerships, co-development agreements, and potential M&A opportunities.
 (2) Pidnarulex (CX-5461) is a globally first-in-class G-quadruplex (G4) stabilizer independently developed by Senhwa and remains the most advanced compound of its kind in development worldwide. It has demonstrated therapeutic potential in advanced hematologic malignancies and multiple solid tumors, including breast, pancreatic, and ovarian cancers. This photodynamic therapy (PDT) study provides preliminary evidence supporting the future development of CX-5461 as a novel PDT strategy, potentially applicable to various cancers, including but not limited to skin cancer.
 (3) Photodynamic therapy (PDT) is a medical technology that combines a photosensitizing agent with a specific wavelength of light to generate singlet oxygen or free radicals, selectively destroying diseased cells or tissues. It is regarded as a minimally invasive treatment modality with relatively low systemic side effects. PDT has been widely used in multiple conditions, including:
 Skin cancers and dermatologic tumors (e.g., basal cell carcinoma, actinic keratosis), Head and neck cancers, Esophageal cancer. Lung cancer, Bladder cancer, Cervical cancer. Market forecasts indicate that the global photodynamic therapy market is expected to grow at a compound annual growth rate (CAGR) of approximately 7%-8% during 2028-2032. In 2024, the oncology-specific PDT market was estimated at approximately US\$3.54 billion and is projected to reach US\$5.89 billion by 2032, reflecting strong demand in the oncology sub-segment. A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments.

6.Countermeasures:

Upload the important information on Market Observation Post System.

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):

None. Drug development requires huge amount of time and investment, and there is no guarantee of success, which may put the investment at risk. Investors should make prudent judgments on investments.